Novavax, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide a clear, complete set of standalone fourth-quarter financial results.
Business context
Novavax is a biotechnology company whose commercial business in 2022 centered on its COVID-19 vaccine, NVX-CoV2373, marketed as Nuvaxovid and under other names in certain markets. The vaccine had authorizations in more than 40 countries. Other development programs include seasonal influenza and a COVID-influenza combination vaccine; malaria work uses the company’s Matrix-M adjuvant. The company remains dependent on COVID-19 vaccine sales, government funding and advance-purchase arrangements.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $1.982 billion | $1.146 billion |
| Product sales | $1.555 billion | None |
| Grant revenue | $382.9 million | $948.7 million |
| Royalties and other | $44.0 million | $197.6 million |
| Cost of sales | $902.6 million | None |
| Research and development | $1.235 billion | $2.535 billion |
| Selling, general and administrative | $488.7 million | $298.4 million |
| Net loss | $657.9 million | $1.744 billion |
| Net loss per share | $8.42 | $23.44 |
| Operating cash flow | $(415.9) million | $322.9 million |
- Reported cost of sales was 58% of product sales, implying a 42% product gross margin before other operating expenses. Cost of sales included $447.6 million of inventory write-downs and $155.9 million of losses on firm purchase commitments. The company’s non-GAAP adjusted cost of sales was approximately $1.067 billion, or 69% of product sales.
- Cash, cash equivalents and restricted cash totaled $1.349 billion at year-end, down from $1.528 billion. Cash and cash equivalents alone were $1.337 billion.
- Year-end current assets were $1.703 billion and current liabilities $2.460 billion, a working-capital deficit of approximately $756.6 million. The current liabilities included $697.4 million associated with the Gavi dispute and $112.5 million due under the amended U.K. agreement.
- Year-end debt included $325 million of 3.75% convertible notes due February 2023 and $175.3 million of 5.00% convertible notes due 2027. Novavax repaid the $325 million notes on January 31, 2023. It raised approximately $236 million net in December 2022 through a common-stock offering and the 2027 notes.
- Management and the auditor disclosed substantial doubt about the company’s ability to continue as a going concern for one year after issuance of the financial statements. The auditor’s financial-statement opinion was unqualified and included a going-concern explanatory paragraph.
Changes versus FY2021
Revenue rose $835.6 million, principally because commercial vaccine sales began in 2022. That increase was partly offset by lower grant revenue, down $565.8 million, and lower royalties and other revenue, down $153.6 million. Net loss narrowed by $1.086 billion, mainly reflecting vaccine sales and lower R&D spending, partly offset by inventory charges and reduced government-funding revenue. Operating cash flow shifted from a $322.9 million inflow to a $415.9 million outflow, reflecting lower advance payments, vendor-payment timing and increased inventory production.
Outlook, material items and risks
- Management expected R&D expenses to decline in 2023 as it adjusts manufacturing capacity and as certain costs may qualify for inventory capitalization. It planned to gate potential Phase 3 influenza and combination-vaccine spending on Phase 2 results expected around mid-2023. The company also said it intended to reduce and control operating spending.
- 2023 revenue depended substantially on developing, manufacturing and commercializing an updated COVID-19 vaccine for the fall season. Early-2023 delays in manufacturing BA.5 trial materials could delay regulatory approval; manufacturing before U.S. strain guidance also risked producing unsellable inventory if the formulation did not match that guidance.
- Gavi disputes termination of its advance purchase agreement and claims a refund of the remaining $697.4 million advance payment. Gavi initiated arbitration in January 2023; Novavax said it believed it could retain the funds but acknowledged that some or all might have to be repaid.
- The U.S. government indicated in February 2023 that its funding award might not extend beyond its current period. If the agreement is not amended, Novavax may not receive the remaining $416 million it had anticipated.
- The U.K. agreement triggered a $112.5 million repayment obligation after a required supportive recommendation was not obtained by November 30, 2022. The European Commission reduced its order by approximately 7 million doses; the remaining 20 million committed doses were rescheduled for delivery in 2023.
- Manufacturing adjustments generated significant costs: the Fujifilm settlement was up to $185 million, with $47.8 million credited and $137.2 million remaining at year-end; Novavax also agreed to approximately $95 million in AGC cancellation fees. Fill-finish for NVX-CoV2373 depended exclusively on SIIPL and SLS.
- Other risks include uncertain vaccine demand and competition, regulatory and manufacturing execution, reliance on third parties, possible additional financing or dilution, and litigation. A Par Sterile Products arbitration had a potential loss that was not reasonably estimable; securities and derivative litigation was also pending.
Important facts for investors to verify
- Whether Novavax can secure adequate 2023 vaccine orders and deliver an updated fall-season formulation on time and in line with regulatory guidance.
- The outcome and timing of Gavi arbitration, including any repayment of the $697.4 million liability.
- Whether U.S. government funding is extended and how much of the anticipated $416 million is ultimately received.
- Cash, working capital and financing needs after the February 2023 note repayment, alongside actual operating cash burn and cost reductions.
- Whether inventory reserves, manufacturer cancellation costs and contractual purchase commitments result in further charges or cash outflows.